论文部分内容阅读
目的:观察败血症新生儿P-选择素和PAF的变化,探讨二者在败血症新生儿病情评估及预后判断中的意义。方法:将56例败血症新生儿进行新生儿危重评分,分为极危重组(13例)、危重组(22例)和非危重组(21例),同时选择健康对照组26例,在入院初期及恢复期采集空腹静脉血,应用酶联免疫吸附试验测定血浆P-选择素和PAF水平,比较败血症极危重组、危重组、非危重组及健康对照组P-选择素和PAF的差异,分析败血症组新生儿治疗前后P-选择素和PAF的变化。结果:败血症极危重组、危重组、非危重组新生儿P-选择素水平分别为(162.51±52.64)μg/L,(131.10±38.61)μg/L,(78.18±32.15)μg/L,较对照组明显升高(P<0.01)。败血症极危重组、危重组、非危重组新生儿PAF水平分别为(9.82±4.04)μg/L,(5.76±2.12)μg/L,(3.84±1.35)μg/L,较对照组明显升高(P<0.05),恢复期PAF水平均明显下降(P<0.01)。新生儿危重病例评分与P-选择素和PAF均呈负相关(r=-0.515,P<0.01,t=-0.473,P<0.01)。结论:检测败血症新生儿的P-选择素和PAF有助于评估病情危重程度及预后,并有针对的开展治疗。
PURPOSE: To observe the changes of P-selectin and PAF in neonates with sepsis and to explore the significance of the two in the evaluation and prognosis of neonatal septicemia. Methods: Fifty-six neonates with septicemia were divided into critically ill group (n = 13), critically ill group (n = 22) and non-critically ill group (n = 21) And recovery of fasting venous blood collected, the application of enzyme-linked immunosorbent assay P-selectin and plasma levels of PAF, sepsis critically ill patients, critically ill patients, non-critically ill patients and healthy controls P-selectin and PAF differences analysis Changes of P - selectin and PAF before and after neonatal sepsis. Results: The levels of P-selectin in critically ill and critically ill neonates were (162.51 ± 52.64) μg / L, (131.10 ± 38.61) μg / L and (78.18 ± 32.15) μg / L respectively) The control group was significantly higher (P <0.01). PAF levels were (9.82 ± 4.04) μg / L, (5.76 ± 2.12) μg / L and (3.84 ± 1.35) μg / L, respectively, in critically ill and critically ill neonates with sepsis, which were significantly higher than those in the control group (P <0.05), PAF levels in convalescent period decreased significantly (P <0.01). Neonatal critically ill case scores were negatively correlated with P-selectin and PAF (r = -0.515, P <0.01, t = -0.473, P <0.01). Conclusion: The detection of P-selectin and PAF in neonates with septicemia can help to assess the severity and prognosis of the disease and to carry out targeted treatment.